Abstract
Objective: To evaluate E-cadherin expression in association with lymph
node metastasis in primary non-small cell lung carcinomas (NSCLC).
Method: The retrospective study included 58 consecutive patients who
underwent radical pulmonary surgery due to primary NSCLC. Staging
was performed in accordance to TNM lung tumour classification by
World Health Organization, 2015 (Travis et al., 2015). E-cadherin expression was detected by immunohistochemistry and evaluated as positive
versus negative using cut-off level at 10 % of positive tumour cells
(Deeb et al., 2004). The statistical analysis comprised descriptive statistics
including calculation of 95 % confidence interval (CI), and MannWhitney test.
Results: The study group comprised 58 primary NSCLC cases. Lymph
node metastases were found in 27 (46.6 %; CI = 34.3–59.2) patients of
which 25 (92.9 %; CI = 77.4–98.0) were assessed as E-cadherin-positive
and 2 (7.1 %; CI = 2.0–22.6) as negative cases. The remaining 31
(53.4 %; CI = 40.8–65.7) cases included pN0 carcinomas. Among these,
23 (74.2 %, CI = 56.8–86.3) tumours were E-cadherin-positive while 8
(25.8 %, CI = 13.7–43.2) cases were negative compared to metastatic
cancers (p = 0.058).
Conclusion: There was a trend to more frequent E-cadherin expression in
NSCLC showing metastatic spread to lymph nodes in contrast to nonmetastatic tumours. The controversies regarding E-cadherin in lung cancer might be attributable to case selection, e.g., including only resectable
tumours; or mesenchymal-epithelial transformation.
node metastasis in primary non-small cell lung carcinomas (NSCLC).
Method: The retrospective study included 58 consecutive patients who
underwent radical pulmonary surgery due to primary NSCLC. Staging
was performed in accordance to TNM lung tumour classification by
World Health Organization, 2015 (Travis et al., 2015). E-cadherin expression was detected by immunohistochemistry and evaluated as positive
versus negative using cut-off level at 10 % of positive tumour cells
(Deeb et al., 2004). The statistical analysis comprised descriptive statistics
including calculation of 95 % confidence interval (CI), and MannWhitney test.
Results: The study group comprised 58 primary NSCLC cases. Lymph
node metastases were found in 27 (46.6 %; CI = 34.3–59.2) patients of
which 25 (92.9 %; CI = 77.4–98.0) were assessed as E-cadherin-positive
and 2 (7.1 %; CI = 2.0–22.6) as negative cases. The remaining 31
(53.4 %; CI = 40.8–65.7) cases included pN0 carcinomas. Among these,
23 (74.2 %, CI = 56.8–86.3) tumours were E-cadherin-positive while 8
(25.8 %, CI = 13.7–43.2) cases were negative compared to metastatic
cancers (p = 0.058).
Conclusion: There was a trend to more frequent E-cadherin expression in
NSCLC showing metastatic spread to lymph nodes in contrast to nonmetastatic tumours. The controversies regarding E-cadherin in lung cancer might be attributable to case selection, e.g., including only resectable
tumours; or mesenchymal-epithelial transformation.
| Original language | English |
|---|---|
| Article number | PS-05-040 |
| Pages (from-to) | S111-S111 |
| Journal | Virchows Archiv |
| Volume | 471 |
| Issue number | Suppl. 1 |
| Publication status | Published - Sept 2017 |
| Event | 29th European Congress of Pathology: Pathology for patient care - Amsterdam, Netherlands Duration: 2 Sept 2017 → 6 Sept 2017 Conference number: 29 https://pathology.nl/evenement/29th-european-congress-of-pathology/ https://www.esp-congress.org/_Resources/Persistent/c6589e10208b86a3700a8c1f36aca4325f15f3a4/ECP2017_Final%20Programme.pdf |
Field of Science*
- 3.2 Clinical medicine
- 3.1 Basic medicine
Publication Type*
- 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database
